Dahap, Jiel Rica B.
HRN: 20-16-74 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/14/2022
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
05/14/2022
05/20/2022
IVT
180MG
OD
Amoebiasis
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes